1. Stocks
    2. /
  2. Imugene Limited (ASX: IMU)
    3. /

Imugene Limited (ASX: IMU) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Imugene Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

    • Imugene Limited (ASX: IMU)
    Latest News

    trophy depicting top 10, asx 200 shares
    Share Market News

    Here are the top 10 ASX 200 shares today

    | Brooke Cooper

    These ASX 200 shares outperformed the index on Monday.

    Read more »

    Health workers shake hands and congratulate each other on good news.
    Healthcare Shares

    What sent the Imugene share price 6% higher this morning?

    | Monica O'Shea

    Why are Imugene shares rising today?

    Read more »

    Five people in an office high five each other.
    Share Market News

    Here are the top 10 ASX 200 shares today

    | Brooke Cooper

    These ASX 200 shares outperformed all others on Thursday.

    Read more »

    A husband and wife dance with their young daughter in their lounge room.
    Share Market News

    Here are the top 10 ASX 200 shares today

    | Brooke Cooper

    These 10 ASX 200 shares outperformed all others on Thursday.

    Read more »

    A group of business people dance around the office looking very happy.
    Share Market News

    Here are the top 10 ASX 200 shares today

    | Brooke Cooper

    These ASX 200 shares defied today's downturn to end the week on a high note.

    Read more »

    A disappointed lab researcher sits in her lab looking at her clipboard with her hand to her face as she worries about the Imugene share price today
    Share Fallers

    Why did the Imugene share price implode 31% in September?

    | Monica O'Shea

    We take a look at how Imugene performed in September.

    Read more »

    A girl lies on her bed in her room while using laptop and listening to headphones.
    Share Market News

    Here are the top 10 ASX 200 shares today

    | Brooke Cooper

    These ASX 200 shares outperformed all others on Tuesday.

    Read more »

    Three guys in shirts and ties give the thumbs down.
    Share Fallers

    Why Imugene, Link, Newcrest, and Zip shares are dropping

    | James Mickleboro

    These ASX shares are having very poor days...

    Read more »

    Top ten gold trophy.
    Share Market News

    Here are the top 10 ASX 200 shares today

    | Brooke Cooper

    These ASX 200 shares outperformed all others on Tuesday.

    Read more »

    Group of Imugene scientists cheering in the lab after the company received another patent for HER-Vaxx
    Healthcare Shares

    Imugene share price leaps 5% on trial news

    | Aaron Teboneras

    Imugene shares are starting the week on a positive note.

    Read more »

    A bored man sits at his desk, flat after seeing the latest news on the share market.
    Healthcare Shares

    Why did the Imugene share price have such a lousy end to the week?

    | Aaron Teboneras

    The Imugene share price has tanked almost 50% since this time last year.

    Read more »

    A sad looking scientist sitting and upset about a share price fall.
    Capital Raising

    Imugene share price sinks on $80 million cap raise

    | Aaron Teboneras

    What did Imugene announce to the market?

    Read more »

    Frequently Asked Questions

    Imugene does not pay dividends at this stage. 

    Imugene Ltd (ASX: IMU) listed on the ASX on 24 November 1993.

    IMU ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Imugene Limited

    Imugene Ltd (ASX: IMU) is a biotechnology company working in cancer immunotherapy.

    The company specialises in clinical-stage immuno-oncology therapies. Its product pipeline includes Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard-care drugs and immunotherapies.

    The company's lead product is HER-Vaxx, a proprietary cancer vaccine for the treatment of gastric and breast cancer, where the cancer is HER-2 positive. The vaccine has demonstrated it stimulates a polyclonal antibody response to HER2/neu. 

    Imugene's various immunotherapy products are involved in ongoing clinical trials involving cancer specialists and researchers worldwide.

    Profile

    since

    Note